Dynavax Technologies Corporation
DVAXDynavax Technologies Corporation (DVAX) is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases, oncology, and autoimmune conditions. The company is known for its COVID-19 vaccine, leveraging its expertise in immunology and vaccine technology to address various public health challenges.
Company News
Class action law firm Monteverde & Associates PC is investigating four merger and acquisition transactions: Dynavax Technologies' sale to Sanofi ($15.50/share), FONAR Corporation's sale to affiliates of its CEO ($19.00-$6.34/share), DigitalBridge Group's sale to SoftBank ($16.00/share), and ON24's sale to Cvent Atlanta ($8.10/share). The firm is ...
Monteverde & Associates PC, a securities class action firm, has announced an investigation into Dynavax Technologies Corporation's proposed acquisition by Sanofi. Under the deal terms, Dynavax shareholders are expected to receive $15.50 per share in cash. The firm is examining whether the transaction represents a fair deal for shareholders.
U.S. stock futures declined on Friday following Wednesday's gains, with major indices showing modest losses. Key movers included Nvidia rising on a licensing agreement with Groq, Dynavax surging 38% on Sanofi acquisition news, Sobr Safe dropping 16% after announcing a private placement, and Biohaven plummeting 14% after a failed clinical trial. E...
U.S. stock indices hover near record highs on Christmas Eve with the S&P 500 up 0.1% and year-to-date gains of 17.5%. Precious metals surge with gold breaking above $4,500/oz (up 70% YTD) and silver up 150%. The market shows mixed tech performance with AI leaders like Nvidia and Alphabet driving gains, while Intel faces pressure after Nvidia halt...
Dynavax Technologies shares surged 38.19% on Wednesday following Sanofi's announcement to acquire the biopharmaceutical company for $15.50 per share in cash, representing approximately $2.2 billion in total equity value. The offer price reflects a 39% premium over Dynavax's closing price on Dec. 23. The acquisition includes HEPLISAV-B, an adult h...
